In this study, we firstly evaluated the pharmacodynamics of PPAR α/δ agonist GFT505 and profile the regulatory network of GFT505 in the CDAHFD induced NASH model. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.